Skip to content
Search

Latest Stories

Rutherford Diagnostic Centre opens in Taunton

A state-of-the-art diagnostics centre giving increased access to tests and serving patients from across Somerset and surrounding areas has officially opened.

The Rutherford Diagnostic Centre Somerset in Taunton, run by Rutherford Diagnostics Limited – a subsidiary of Rutherford Health PLC – in partnership with Somerset NHS Foundation Trust, is the first community diagnostics centre of its kind in England


It will provide diagnostic services including Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound and X-Ray on equipment provided by Rutherford’s technology partner, Philips.

Rutherford 090921 124

The centre was inaugurated by the renowned cancer specialist, Professor Sir Mike Richards CBE, former National Cancer director in the Department of Health.

Professor Richards said: “I’m delighted to have formally opened the first community diagnostics centre run by the independent sector in partnership with the NHS. Even prior to the pandemic the need for more diagnostic services was very clear and the last 18 months have underlined how important it is to rise to meet this challenge successfully.”

Somerset NHS Foundation Trust entered into a partnership with Rutherford Diagnostics Limited in June 2020 amid concerns that the trust might not be able to keep pace with demand for diagnostic tests in the future.

Peter Lewis, chief executive of Somerset NHS Foundation Trust, said: “This is a fantastic facility for patients in Somerset and the surrounding areas.

“As a result our patients have access to diagnostic tests at this modern stand-alone facility away from a busy hospital. This is part of the new recommended way forward for the NHS and has become more important as a result of the global pandemic.

“It also brings real benefits for our radiology, radiographic and booking colleagues who will be working alongside Rutherford’s staff in the centre, enabling them to work in more diverse environments and expand their experience.”

The centre will also help the trust to prioritise its capacity usage at Musgrove Park Hospital for emergency patients or those who are already in the hospital.

Lewis added: “This is not only good for our patients, but also the way we care for people across the whole Somerset healthcare system by enabling them to have imaging scans away from the acute hospital.”

Besides, the additional capacity at the centre will enable the trust to increase its CT capacity by a quarter immediately and its MRI capacity by a quarter within three months.

The centre is the first of the five that Rutherford intends to develop under an agreement between Rutherford Health plc and Equitix, a leading investor, developer in the UK and Europe. Philips will provide the innovative technology at all five sites.

Mike Moran, chief executive officer of Rutherford Health, said: “There has never been a more important time for innovative partnering in healthcare in the UK, to ensure patients get access to earlier diagnosis and the best treatment as quickly as possible.

“This centre is a major step forward in addressing the rising demand for diagnostic services across Somerset and we are delighted to be working in collaboration with the Somerset NHS Foundation Trust to deliver tangible benefit to their patients.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less